CN105456903A - 一种治疗更年期焦虑症合并精神倦怠的药物组合物 - Google Patents
一种治疗更年期焦虑症合并精神倦怠的药物组合物 Download PDFInfo
- Publication number
- CN105456903A CN105456903A CN201610038111.0A CN201610038111A CN105456903A CN 105456903 A CN105456903 A CN 105456903A CN 201610038111 A CN201610038111 A CN 201610038111A CN 105456903 A CN105456903 A CN 105456903A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- herba
- flos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title abstract description 10
- 230000009245 menopause Effects 0.000 title abstract 3
- 239000002184 metal Substances 0.000 title abstract 3
- 241000628997 Flos Species 0.000 claims abstract description 53
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- 241000366349 Cissus pteroclada Species 0.000 claims abstract description 19
- 241001407408 Berberis fortunei Species 0.000 claims abstract description 17
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 17
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- 230000036506 anxiety Effects 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 18
- 241000180649 Panax notoginseng Species 0.000 claims description 18
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 241001649190 Campsis Species 0.000 claims description 16
- 244000025254 Cannabis sativa Species 0.000 claims description 16
- 241000218628 Ginkgo Species 0.000 claims description 16
- 206010016256 fatigue Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 238000002474 experimental method Methods 0.000 abstract description 6
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241001346334 Amomum tsao-ko Species 0.000 abstract 1
- 241001546929 Campsis grandiflora Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 244000219416 Hypericum japonicum Species 0.000 abstract 1
- 244000100135 Melanthera biflora Species 0.000 abstract 1
- 244000174681 Michelia champaca Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241001522232 Pinellia ternata Species 0.000 abstract 1
- 240000004064 Poterium sanguisorba Species 0.000 abstract 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 240000003377 Shepherdia canadensis Species 0.000 abstract 1
- 235000018324 Shepherdia canadensis Nutrition 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 239000013641 positive control Substances 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 10
- 230000002929 anti-fatigue Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 241000345998 Calamus manan Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000009661 fatigue test Methods 0.000 description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001047513 Mus musculus Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229950005162 benexate Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,涉及一种治疗更年期焦虑症合并精神倦怠的药物组合物及其制备方法。为了克服现有技术不足,本发明提供一种能够改善睡眠质量以及抗疲劳的药物组合物,它主要由以下原料制得:三七8-20份、决明子5-15份、鱼腥草5-15份、马兰草3-10份、款冬花10-25份、茯苓皮5-15份、无患子10-20份、仙鹤草3-10份、香橼10-20份、桂枝5-15份、徐长卿8-20份、四方藤5-12份、怀牛膝10-20份、含笑3-10份、十大功劳5-15份、银杏叶3-10份、地耳草3-10份、地榆5-12份、凌霄花10-15份、辛夷花10-20份、半夏5-15份、丹参5-15份、草果5-25份、甘草10-20份。药理实验和临床实验证实其具有显著的治疗更年期焦虑症合并精神倦怠的效果,因而具有广阔的医学推广价值。
Description
技术领域
本发明属于中药技术领域,特别是涉及一种用于治疗更年期焦虑症合并精神倦怠的药物组合物及其制备方法。
背景技术
更年期焦虑症指由于长期处于紧张和压力下,出现精神易兴奋和脑力易疲乏现象,常伴有情绪烦恼、易激惹、睡眠障碍、肌肉紧张性疼痛等症状;这些症状不能归于脑、躯体疾病及其他精神疾病。症状时轻时重,波动与心理社会因素有关,病程多迁延。
引起更年期焦虑症的原因较为复杂,目前大多数学者认为精神因素是造成更年期焦虑症的主因。凡是能引起持续的紧张心情和长期的内心矛盾的一些因素,使神经活动过程强烈而持久的处于紧张状态,超过神经系统张力的耐受限度,即可发生更年期焦虑症。如过度疲劳而又得不到休息是兴奋过程过度紧张;对现在状况不满意则是抑制过程过度紧张;经常改变生活环境而又不适应,中枢神经系统的活动,在机体各项活动中起主导作用。而大脑皮质的神经细胞具有相当高的耐受性,一般情况下并不容易引起更年期焦虑症或衰竭。在紧张的脑力劳动之后,虽然产生了疲劳,但稍事休憩或睡眠后就可以恢复,但是,强烈紧张状态的神经活动,一旦超越耐受极限,就可能产生更年期焦虑症。
目前临床上对于更年期焦虑症的治疗的药物较多,如抗焦虑、抗抑郁药物可改善患者的焦虑和抑郁,也可使肌肉放松,消除一些躯体不适感。其他治疗包括体育锻炼,旅游疗养,也有助于短期改善紧张状态、缓解精神压力。但西医治疗药物多具有严重的毒副作用,而短期生活方式的治疗则复发率高,并不能从根本上治愈更年期焦虑症中医药是我国医学科学的特色,通过辨证论治的方法在治疗更年期焦虑症方面积累了丰富的临床经验。目前临床上使用的中药对于更年期焦虑症的疗效不确切,特别是长期用药效果不佳,本发明旨在提供一种治疗效果确切,治疗成本低的更年期焦虑症治疗药物。
发明内容
现有技术中化学药物治标不治本,且药物毒副作用大,而中药则存在疗效不确定,缺少相应药物制剂。为了克服上述现有技术的不足,本发明的目的是提供一种能够有效治疗更年期焦虑症合并精神倦怠的药物组合物,其见效快、疗程短、治愈率高,适合开发成临床治疗药物。
为实现本发明的目的,现依据了如下的技术方案,本发明中药是由以下重量份配比的原料制成:
三七8-20份、决明子5-15份、鱼腥草5-15份、马兰草3-10份、款冬花10-25份、茯苓皮5-15份、无患子10-20份、仙鹤草3-10份、香橼10-20份、桂枝5-15份、徐长卿8-20份、四方藤5-12份、怀牛膝10-20份、含笑3-10份、十大功劳5-15份、银杏叶3-10份、地耳草3-10份、地榆5-12份、凌霄花10-15份、辛夷花10-20份、半夏5-15份、丹参5-15份、草果5-25份、甘草10-20份;
根据药物组合物对更年期焦虑症合并精神倦怠治疗效果的差异,在上述药物组合物基础上优选如下:
(一)三七15份、决明子10份、鱼腥草10份、马兰草7份、款冬花18份、茯苓皮10份、无患子15份、仙鹤草7份、香橼15份、桂枝10份、徐长卿14份、四方藤9份、怀牛膝15份、含笑7份、十大功劳10份、银杏叶7份、地耳草6份、地榆8份、凌霄花13份、辛夷花15份、半夏10份、丹参10份、草果20份、甘草15份。
(二)三七8份、决明子5份、鱼腥草5份、马兰草3份、款冬花10份、茯苓皮5份、无患子10份、仙鹤草3份、香橼10份、桂枝5份、徐长卿8份、四方藤5份、怀牛膝10份、含笑3份、十大功劳5份、银杏叶3份、地耳草3份、地榆5份、凌霄花10份、辛夷花10份、半夏5份、丹参5份、草果5份、甘草10份。
(三)三七20份、决明子15份、鱼腥草15份、马兰草10份、款冬花25份、茯苓皮15份、无患子20份、仙鹤草10份、香橼20份、桂枝15份、徐长卿20份、四方藤12份、怀牛膝20份、含笑10份、十大功劳15份、银杏叶10份、地耳草10份、地榆12份、凌霄花15份、辛夷花20份、半夏15份、丹参15份、草果25份、甘草20份。
(四)三七12份、决明子12份、鱼腥草10份、马兰草5份、款冬花16份、茯苓皮18份、无患子13份、仙鹤草6份、香橼20份、桂枝10份、徐长卿10份、四方藤8份、怀牛膝16份、含笑6份、十大功劳10份、银杏叶5份、地耳草8份、地榆7份、凌霄花8份、辛夷花14份、半夏5份、丹参15份、草果15份、甘草17份。
为了更好地表达本发明的药物组合物,本发明的药物组合物可以制备成临床上常用的剂型。比如,粉状制剂、散剂、丸剂、丹剂、膏剂、颗粒剂、口服液、糖浆、片剂、胶囊剂等制剂,所述药物制剂均可按照本领域技术人员所熟知的中药制剂制备方法制备得到。优选地,本发明药物组合物按照常规制备工艺制备成散剂、水剂、片剂或胶囊剂。
本发明还提供了一种上述所述药物组合物的制备方法,其主要包含下述步骤:取处方量上述中药材碎成粗粉,按照粗粉总重量的4~9倍加入体积浓度为40%~95%的乙醇溶液,回流提取三次,回流时间为2~5h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;本领域技术人员可在该制备方法技术上制备得到临床上常用中药药物剂型,如片剂、胶囊剂等。
本发明还请求保护上述药物组合物在制备治疗更年期焦虑症合并精神倦怠药物中的用途。其中所述的更年期焦虑症合并精神倦怠具有睡眠障碍、血瘀、易疲劳倦怠、易衰老中的一种症状或症状组合。本发明药物组合物在治疗更年期焦虑症合并精神倦怠时,显示出显著抗疲劳、抗氧自由基、活血化淤以及改善睡眠质量的活性。本发明药效实施例7显示,给予阳性药物和本发明药物组合物均能取得显著的抗疲劳作用和改善睡眠质量的作用,其中本发明药物组合物高剂量组的抗疲劳作用和改善睡眠质量的作用与阳性对照组具有极显著差异,药物组合物中剂量组与阳性对照组具有显著性差异,这表明本发明药物组合物的高剂量组和低剂量组的抗疲劳作用和改善睡眠质量的作用要显著优于阳性对照组,本发明药物组合物在降低更年期焦虑症合并精神倦怠患者的疲劳反应和改善睡眠质量方面具有比现有治疗药物更优异的治疗效果。
总之,本发明药物组合物在治疗更年期焦虑症合并精神倦怠方面,与现有技术相比具有如下优势:
1)与当前治疗的化学治疗药物相比,本发明药物组合物为天然纯中药制剂,不良反应和副作用显著降低,且本发明药物组合物作用全面,药物治疗效果更佳,显著提高了更年期焦虑症合并精神倦怠患者的用药依从性,并提高了患者的生活质量。
2)本发明药物组合物中含有多种药物组分,作用靶点众多,药理实验显示其具有显著的抗疲劳和改善睡眠等活性,有效地解决了更年期焦虑症合并精神倦怠的发病根源,其对更年期焦虑症合并精神倦怠的治疗效果起到了标本兼治的效果。
3)本发明是发明人在祖传秘方的基础上,结合多年临床经验的总结,经过反复实验而得,因此该药物对各种原因引起的更年期焦虑症合并精神倦怠有独特的疗效,该药配伍科学,疗效迅速,见效快、疗程短、治愈率高、费用小的优点。
具体实施方式
以下通过具体实施例进一步描述本发明,但本领域技术人员应该知晓,所述实施例并不以任何方式限制本发明。
(一)制剂实施例部分
实施例1本发明药物组合物及制备工艺
处方组成如下:
三七8kg、决明子5kg、鱼腥草5kg、马兰草3kg、款冬花10kg、茯苓皮5kg、无患子10kg、仙鹤草3kg、香橼10kg、桂枝5kg、徐长卿8kg、四方藤5kg、怀牛膝10kg、含笑3kg、十大功劳5kg、银杏叶3kg、地耳草3kg、地榆5kg、凌霄花10kg、辛夷花10kg、半夏5kg、丹参5kg、草果5kg、甘草10kg;
制备方法:取处方量上述中药材碎成粗粉,按照粗粉总重量的4倍加入体积浓度为40%的乙醇溶液,回流提取三次,回流时间为5h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;将中药浸膏粉碎并加入制剂常用辅料制备成片剂或胶囊剂。
实施例2本发明药物组合物及制备工艺
处方组成如下:
三七20kg、决明子15kg、鱼腥草15kg、马兰草10kg、款冬花25kg、茯苓皮15kg、无患子20kg、仙鹤草10kg、香橼20kg、桂枝15kg、徐长卿20kg、四方藤12kg、怀牛膝20kg、含笑10kg、十大功劳15kg、银杏叶10kg、地耳草10kg、地榆12kg、凌霄花15kg、辛夷花20kg、半夏15kg、丹参15kg、草果25kg、甘草20kg;
制备方法:取处方量上述中药材碎成粗粉,按照粗粉总重量的5倍加入体积浓度为90%的乙醇溶液,回流提取三次,回流时间为3h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;将中药浸膏粉碎并加入制剂常用辅料制备成片剂或胶囊剂。
实施例3本发明药物组合物及制备工艺
处方组成如下:
三七15kg、决明子10kg、鱼腥草10kg、马兰草7kg、款冬花18kg、茯苓皮10kg、无患子15kg、仙鹤草7kg、香橼15kg、桂枝10kg、徐长卿14kg、四方藤9kg、怀牛膝15kg、含笑7kg、十大功劳10kg、银杏叶7kg、地耳草6kg、地榆8kg、凌霄花13kg、辛夷花15kg、半夏10kg、丹参10kg、草果20kg、甘草15kg;
制备方法:取处方量上述中药材碎成粗粉,按照粗粉总重量的5倍加入体积浓度为70%的乙醇溶液,回流提取三次,回流时间为4h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;将中药浸膏粉碎并加入制剂常用辅料制备成片剂或胶囊剂。
实施例4本发明药物组合物及制备工艺
处方组成如下:
三七8kg、决明子15kg、鱼腥草15kg、马兰草3kg、款冬花25kg、茯苓皮15kg、无患子10kg、仙鹤草10kg、香橼10kg、桂枝10kg、徐长卿16kg、四方藤12kg、怀牛膝10kg、含笑3kg、十大功劳5kg、银杏叶10kg、地耳草10kg、地榆7kg、凌霄花10kg、辛夷花15kg、半夏10kg、丹参10kg、草果10kg、甘草10kg;
制备方法:取处方量上述中药材碎成粗粉,按照粗粉总重量的5倍加入体积浓度为70%的乙醇溶液,回流提取三次,回流时间为4h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;加入乙醇至含醇量为75%(v/v),静置24小时,取上清液,回收乙醇浓缩,加水至1000ml,搅匀,分装,流通蒸汽灭菌35min,即得合剂。
实施例5本发明药物组合物及制备工艺
处方组成如下:
三七12kg、决明子12kg、鱼腥草10kg、马兰草5kg、款冬花16kg、茯苓皮18kg、无患子13kg、仙鹤草6kg、香橼20kg、桂枝10kg、徐长卿10kg、四方藤8kg、怀牛膝16kg、含笑6kg、十大功劳10kg、银杏叶5kg、地耳草8kg、地榆7kg、凌霄花8kg、辛夷花14kg、半夏5kg、丹参15kg、草果15kg、甘草17kg;
制备方法同实施例4。
实施例6本发明药物组合物及制备工艺
处方组成如下:
三七14kg、决明子10kg、鱼腥草13kg、马兰草6kg、款冬花20kg、茯苓皮15kg、无患子20kg、仙鹤草3kg、香橼16kg、桂枝9kg、徐长卿11kg、四方藤7kg、怀牛膝16kg、含笑7kg、十大功劳11kg、银杏叶5kg、地耳草10kg、地榆12kg、凌霄花15kg、辛夷花16kg、半夏15kg、丹参12kg、草果18kg、甘草17kg;
制备工艺同实施例4。
(二)药效实施例部分
实施例7本发明药物组合物抗疲劳试验和睡眠改善作用
抗疲劳实验:取健康昆明种小鼠,体重18~22g小鼠50只,随机分为5组。每组10只,雌雄各5只,分组情况见表2。各组动物ig给药,阳性药物组ig妇康宁片剂,药物组合物分别给逾按照本发明实施例1制备的片剂,各组给药剂量如表1所示,给药前用生理盐水溶解,正常对照组ig等量生理盐水。各组连续给药10天,末次给药后1h,将小鼠放入水温为20℃的水槽内游泳。直至小鼠沉入水底,计算游泳时间。
睡眠改善实验:另取健康昆明种小鼠,体重20~22g小鼠50只,随机分为5组,每组10只,雄雌各5只。分组情况及给药剂量同上述抗疲劳试验设计,连续给药5天。末次药后1h,以35mg/kg的剂量小鼠ig戊巴比妥钠,以翻正反射消失为指标,记录小鼠睡眠时间。
小鼠的抗疲劳实验结果和睡眠改善实验结果如表1所示。
表1本发明药物组合物的抗疲劳实验结果和睡眠改善实验结果
| 组别 | 剂量(按生药量计) | n | 游泳时间 | 睡眠时间 |
| 正常对照组 | 等体积生理盐水 | 10 | 6.58±1.35 | 25.61±5.34 |
| 阳性对照组 | 7.5mg/kg | 10 | 9.26±1.74* | 29.34±7.54* |
| 药物组合物低组 | 7.5mg/kg | 10 | 9.47±1.53* | 28.39±8.24* |
| 药物组合物中组 | 10mg/kg | 10 | 11.27±1.78**# | 32.69±6.95**# |
| 药物组合物高组 | 15mg/kg | 10 | 13.25±1.95**## | 35.97±8.69**## |
与模型对照组比较,*P<0.05;与模型对照组比较,**P<0.01;
与阳性对照组比较,#P<0.05;与阳性对照组比较,##P<0.01。
结果显示给予阳性药物和本发明药物组合物均能取得显著的抗疲劳作用,其中本发明药物组合物高剂量组的抗疲劳作用与阳性对照组具有极显著差异,药物组合物中剂量组与阳性对照组具有显著性差异,这表明本发明药物组合物的高剂量组和中剂量组的抗疲劳作用要显著优于阳性对照组,本发明药物组合物在降低更年期焦虑症合并精神倦怠患者的疲劳反应具有比现有治疗药物更优异的治疗效果。
给予阳性药物和本发明药物组合物均能取得显著的睡眠质量改善作用,其中本发明药物组合物高剂量组的睡眠质量改善作用与阳性对照组具有极显著差异,药物组合物中剂量组与阳性对照组具有显著性差异,这表明本发明药物组合物的高剂量组和中剂量组的抗疲劳作用要显著优于阳性对照组,本发明药物组合物在改善更年期焦虑症合并精神倦怠患者的睡眠质量方面具有比现有治疗药物更优异的治疗效果。
实施例8本发明药物组合物的毒性实验
1、实验目的:确定药物组合物的一般毒性以及肝肾毒性。
2、受试药物:
按上述实施例1的制备方法制备:即其由如下重量Kg的中药组分制备得到:辛夷花45Kg、鱼腥草5.5Kg、牡蛎30Kg、厚朴25Kg、白花蛇舌草30Kg、鸡心藤85Kg、紫草15Kg、丹参12Kg、含笑5Kg、四方藤9Kg、三七10Kg、山楂6Kg、枳实10Kg。其包括如下步骤:(1)取牡蛎、白花蛇舌草、丹参、四方藤和三七加水浸泡1小时,用挥发油提取器提取挥发油,再用无水硫酸钠干燥取得挥发油,再用β-环糊精包合,制得包合物,包合物及药渣备用;(2)取鸡心藤、辛夷花、含笑、紫草和海棠叶加70%乙醇提取2次,每次1.5小时,合并药液,静置24小时,备用;(3)取厚朴、鱼腥草、山楂、枳实和款冬花粉碎成细粉和步骤(1)中药渣混合后用适量75%乙醇提取2次,每次1小时,收集提取液,静置24小时,备用;(4)取第(2)和(3)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.03的浸膏,干燥后备用,向浸膏中加入第(1)步骤中制得的β-环糊精包合物,测定其重量,加入其重量10%的乳糖和糊精的混合物,其中乳糖和糊精的混合物中乳糖和糊精的重量比为2:1;搅拌均匀加热至80℃,过100目筛,用喷雾干燥机制得提取物粉末,分装即得颗粒剂。
3、实验方法及指标测定:
SD大鼠,雌雄各半,随机分为4组,每组10只,按大剂量组(20g/kg),中剂量组(10g/kg),小剂量组(5g/kg)灌胃给药,空白组灌服同等体积的生理盐水,大鼠稳定3d进入试验,每日灌胃1次,连续给药30天。
一般指标测定:期间观察大鼠一般状况、行为活动、每10d称一次体重。
肝功能指标测定:末次药后24h(禁食不禁水12h),眶静脉采血、凝血,常规离心,制备血清,采用试剂盒方法,用全自动生化分析仪进行血液生化学检查。
肾功能指标测定:实验结束时尾静脉采血,代谢笼收集24小时尿液,测定尿B2MG、尿AKP、尿Lys。处死大鼠,留取肾脏作病理检验。
4、实验结果
4.1一般指标测定结果
表2药物组合物对大鼠体重的影响
| 组别 | 给药前3d | 给药0d | 给药10d | 给药20d | 给药30d |
| 空白组 | 149.87±16.36 | 155.30±18.04 | 170.33±18.75 | 183.23±20.06 | 201.86±19.36 |
| 大剂量组 | 150.03±18.17 | 156.37±16.31 | 172.17±22.32 | 185.21±19.87 | 200.05±18.14 |
| 中剂量组 | 148.32±18.36 | 154.94±17.26 | 173.43±19.63 | 182.19±18.49 | 198.38±18.35 |
| 小剂量组 | 148.66±19.83 | 156.41±17.48 | 169.71±14.38 | 184.20±22.19 | 203.63±19.84 |
表2实验结果显示,药物组合物大剂量组、中剂量组以及小剂量组在给药期间与空白组相比,在大鼠的体重方面无显著性差异。各给药组均未出现死亡,一般状况以及行为活动与空白组比较无明显差异。
4.2肝功能指标测定结果
表3药物组合物对大鼠转氨酶的影响
| 组别 | ALT/U·L-1 | AST/U·L-1 |
| 空白组 | 76.10±5.32 | 192.60±20.41 |
| 大剂量组 | 82.70±8.03 | 206.00±54.60 |
| 中剂量组 | 79.90±5.24 | 194.10±46.94 |
| 小剂量组 | 81.20±7.48 | 197.60±37.18 |
表3实验结果显示,药物组合物大剂量组、中剂量组以及小剂量组在给药期间与空白组相比,在大鼠的转氨酶含量方面无显著性差异。
4.3肾功能指标测定结果
表4药物组合物对大鼠肾功能指标的影响
| 组别 | Scr/μmol·L-1 | 尿B2MG/ng·mL-1 | 尿AKP/IU·L-1 | 尿Lys/mg·L-1 |
| 空白组 | 109.86±6.36 | 0.030±0.004 | 10.33±1.75 | 0.23±0.04 |
| 大剂量组 | 110.00±8.14 | 0.034±0.002 | 10.17±2.32 | 0.21±0.07 |
| 中剂量组 | 108.38±8.35 | 0.033±0.005 | 11.43±1.62 | 0.19±0.09 |
| 小剂量组 | 108.63±9.84 | 0.031±0.004 | 9.71±4.35 | 0.20±0.09 |
表4实验结果显示,药物组合物大剂量组、中剂量组以及小剂量组在给药期间与空白组相比,在大鼠的肾功能指标(Scr、尿B2MG、尿AKP以及尿Lys)方面无显著性差异。
组织形态的改变:空白组镜下肾单位结构清晰,无管型,无增生性肾小球肾炎,无肾小管坏死,无炎细胞浸润。大剂量组、中剂量组以及小剂量组在肾组织形态改变方面与空白组无差异。
5、实验结论
药物组合物在大鼠给药量5g/kg/d-20g/kg/d的范围内对大鼠的一般生存状态无影响,对大鼠的肝肾功能无影响,该剂量范围内用药安全。
Claims (9)
1.一种治疗更年期焦虑症合并精神倦怠的药物组合物,其特征在于,所述的药物组合物主要由以下重量份的原料制得:三七8-20份、决明子5-15份、鱼腥草5-15份、马兰草3-10份、款冬花10-25份、茯苓皮5-15份、无患子10-20份、仙鹤草3-10份、香橼10-20份、桂枝5-15份、徐长卿8-20份、四方藤5-12份、怀牛膝10-20份、含笑3-10份、十大功劳5-15份、银杏叶3-10份、地耳草3-10份、地榆5-12份、凌霄花10-15份、辛夷花10-20份、半夏5-15份、丹参5-15份、草果5-25份、甘草10-20份。
2.如权利要求1所述的药物组合物,其特征在于,所述的药物组合物主要由以下重量份的原料制得:三七15份、决明子10份、鱼腥草10份、马兰草7份、款冬花18份、茯苓皮10份、无患子15份、仙鹤草7份、香橼15份、桂枝10份、徐长卿14份、四方藤9份、怀牛膝15份、含笑7份、十大功劳10份、银杏叶7份、地耳草6份、地榆8份、凌霄花13份、辛夷花15份、半夏10份、丹参10份、草果20份、甘草15份。
3.如权利要求1所述的药物组合物,其特征在于,所述的药物组合物主要由以下重量份的原料制得:三七8份、决明子5份、鱼腥草5份、马兰草3份、款冬花10份、茯苓皮5份、无患子10份、仙鹤草3份、香橼10份、桂枝5份、徐长卿8份、四方藤5份、怀牛膝10份、含笑3份、十大功劳5份、银杏叶3份、地耳草3份、地榆5份、凌霄花10份、辛夷花10份、半夏5份、丹参5份、草果5份、甘草10份。
4.如权利要求1所述的药物组合物,其特征在于,所述的药物组合物主要由以下重量份的原料制得:三七20份、决明子15份、鱼腥草15份、马兰草10份、款冬花25份、茯苓皮15份、无患子20份、仙鹤草10份、香橼20份、桂枝15份、徐长卿20份、四方藤12份、怀牛膝20份、含笑10份、十大功劳15份、银杏叶10份、地耳草10份、地榆12份、凌霄花15份、辛夷花20份、半夏15份、丹参15份、草果25份、甘草20份。
5.如权利要求1所述的药物组合物,其特征在于,所述的药物组合物主要由以下重量份的原料制得:三七12份、决明子12份、鱼腥草10份、马兰草5份、款冬花16份、茯苓皮18份、无患子13份、仙鹤草6份、香橼20份、桂枝10份、徐长卿10份、四方藤8份、怀牛膝16份、含笑6份、十大功劳10份、银杏叶5份、地耳草8份、地榆7份、凌霄花8份、辛夷花14份、半夏5份、丹参15份、草果15份、甘草17份。
6.如权利要求1-5任一所述的药物组合物,其特征在于,所述的药物组合物为散剂、水剂、片剂或胶囊剂。
7.一种制备权利要求1-5任一所述药物组合物的方法,其特征在于,所述制备方法包括如下步骤:取处方量上述中药材碎成粗粉,按照粗粉总重量的4~9倍加入体积浓度为40%~95%的乙醇溶液,回流提取三次,回流时间为2~5h,滤过,滤液回收乙醇,冷却过滤,用水洗涤,干燥后即得中药浸膏;本领域技术人员可在该制备方法技术上制备得到临床上常用中药药物剂型。
8.权利要求1-5所述的药物组合物在制备更年期焦虑症合并精神倦怠治疗药物中的用途。
9.如权利要求8所述的用途,其特征在于,所述的更年期焦虑症合并精神倦怠具有睡眠障碍、血瘀、易疲劳倦怠、易衰老中的一种症状或两种以上症状组合。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038111.0A CN105456903A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗更年期焦虑症合并精神倦怠的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038111.0A CN105456903A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗更年期焦虑症合并精神倦怠的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456903A true CN105456903A (zh) | 2016-04-06 |
Family
ID=55595352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610038111.0A Withdrawn CN105456903A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗更年期焦虑症合并精神倦怠的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456903A (zh) |
-
2016
- 2016-01-20 CN CN201610038111.0A patent/CN105456903A/zh not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| 霍军等: "女性更年期焦虑的中西医对比治疗研究", 《医药论坛杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8747913B2 (en) | Herbal extract pharmaceutical composition and method for treating and/or preventing of hyperlipidemia and processes for producing the same | |
| CN112891399A (zh) | 一种中药组合物及其用途和制备方法 | |
| CN103933346B (zh) | 一种降糖组合物及其制备方法 | |
| CN101711835B (zh) | 一种治疗软组织损伤的中药配方及其制剂的制备方法 | |
| CN104958494A (zh) | 一种药物组合物在制备治疗妇科出血症药物中的用途 | |
| CN104491733A (zh) | 一种中药制剂用于制备治疗贫血、气虚乏力药物中的用途 | |
| CN1259955C (zh) | 一种治疗妇女更年期综合征的中药制剂 | |
| CN117018156B (zh) | 黄芪桂枝五物汤优化方在制备预防和/或治疗奥沙利铂导致的心脏毒性药物中的应用 | |
| CN104306662A (zh) | 一种治疗神经衰弱的中药组合物及其制备方法 | |
| CN102293985B (zh) | 用于治疗冠心病的中药组合物及其制备方法 | |
| CN101732585A (zh) | 一种治疗偏头痛的药物组合物、制备方法及用途 | |
| CN111419946A (zh) | 一种治疗不育症的药物及其制备方法 | |
| CN104547910A (zh) | 黄莪胶囊的药物用途 | |
| CN100387293C (zh) | 一种药物组合物及其制备方法 | |
| DE102004014005A1 (de) | Pharmazeutische Zusammensetzung zur Prophylaxe oder Behandlung von Osteoporose und Verfahren zu deren Herstellung | |
| CN105456903A (zh) | 一种治疗更年期焦虑症合并精神倦怠的药物组合物 | |
| CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
| CN101036708A (zh) | 治疗心脑血管疾病的药物组合物 | |
| CN101244127B (zh) | 用于治疗血管性痴呆症的药物 | |
| CN106075361B (zh) | 一种中药组合物及其制备与应用 | |
| CN104547105A (zh) | 一种降血糖的药剂 | |
| CN1927324A (zh) | 用于治疗妇女月经不调中药制剂的制备方法 | |
| CN103301429B (zh) | 治疗妇女痛经的口服制剂 | |
| CN100502885C (zh) | 一种治疗痛经的药物组合物及其制备方法 | |
| CN101357177B (zh) | 一种防治中浆病的中药及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160406 |
|
| WW01 | Invention patent application withdrawn after publication |